Clinical Trial Update: Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluated a Factor Xa inhibitor for prevention of venous thromboembolism in patients undergoing elective total knee replacement.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Factor Xa inhibitor

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Thromboembolism | Phase 2 | Status: COMPLETED